Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 1;21(5):939-41.
doi: 10.1158/1078-0432.CCR-14-2549.

CCR 20th anniversary commentary: In the beginning, there was PS-341

Beverly A Teicher  1 , Kenneth C Anderson  2
Affiliations

CCR 20th anniversary commentary: In the beginning, there was PS-341

Beverly A Teicher et al. Clin Cancer Res. .

Abstract

Proteasome inhibitors have a 20-year history in cancer therapy. The first proteasome inhibitor, bortezomib, a breakthrough treatment for multiple myeloma, moved rapidly through development from the bench in 1994 to first FDA approval in 2003. Clinical Cancer Research has chronicled the development of proteasome inhibitors with publication of reports on bortezomib, carfilzomib, and the oral proteasome inhibitor ixazomib (MLN9708).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Timeline for the discovery and development of proteasome inhibitor anticancer agents highlighting the contribution of CCR to communicating important findings.
See this image and copyright information in PMC

References

    1. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the Nf-kB1 precursor protein and activation of NF-kB. Cell. 1994;78:773–85. - PubMed
    1. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5:2638–45. - PubMed
    1. Sunwoo JB, Chen Z, Dong G, Yeh N, Bancroft CC, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419–28. - PubMed
    1. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136–44. - PubMed
    1. Gupta S, inventor US Health, applicant. Formulation of boronic acid compounds. 2002 Aug 1; United States patent US WO2002059130.

MeSH terms